Q-omics provides the consensus-scored KATNIP profile across patient tissues and cancer cell-line models. KATNIP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KATNIP is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, KATNIP RNA expression shows 20,616 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRP, and UVM as cancer lineages where KATNIP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KATNIP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KATNIP survival associations across molecular data types. KATNIP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KATNIP RNA expression–survival associations across cancer types. High KATNIP expression shows unfavorable associations in LGG, BLCA, SKCM and COAD, but favorable associations in HNSC and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KATNIP RNA expression.
This table summarizes KATNIP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KATNIP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KATNIP shows lower tumor expression in THCA and higher tumor expression in KIRP, LIHC, BRCA, BLCA and CHOL. The KIRP box plot shows higher KATNIP RNA expression in tumor versus normal tissue (log2 FC = +0.795, t-test p < 0.001).
This table shows molecular features associated with KATNIP in patient tissues and cancer cell lines. In patient samples, KATNIP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KATNIP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
